Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial.
L GuglielmettiE ArdizzoniM AtgerE BaudinE BerikovaM BonnetE ChangS CloezJ M CoitV CoxB C de JongC DeliferJ M DoD Dos Santos TozziV DucherG FerlazzoM GouillouA KhanU KhanN LachenalA N LaHoodL LeccaM MazmanianH McIlleronM MoschioniK O'BrienO OkunborL OyewusiS PandaS B PatilP P J PhillipsL PichonP RupasingheM L RichN SaluhuddinK J SeungM TamiratL TrippaM CellamareG E VelásquezS WassermanP J ZimetbaumF VaraineCarole D MitnickPublished in: Trials (2021)
ClinicalTrials.gov Identifier NCT02754765. Registered on 28 April 2016; the record was last updated for study protocol version 3.3, on 27 August 2019.
Keyphrases
- study protocol
- multidrug resistant
- randomized controlled trial
- drug resistant
- mycobacterium tuberculosis
- gram negative
- acinetobacter baumannii
- psychometric properties
- klebsiella pneumoniae
- pulmonary tuberculosis
- drug administration
- clinical trial
- open label
- hiv aids
- adverse drug
- systematic review
- drug induced
- placebo controlled
- human immunodeficiency virus